134 related articles for article (PubMed ID: 38178286)
21. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models.
Mykytyn AZ; Breugem TI; Geurts MH; Beumer J; Schipper D; van Acker R; van den Doel PB; van Royen ME; Zhang J; Clevers H; Haagmans BL; Lamers MM
J Virol; 2023 Aug; 97(8):e0085123. PubMed ID: 37555660
[TBL] [Abstract][Full Text] [Related]
23. BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry.
Moumbock AFA; Tran HTT; Lamy E; Günther S
Arch Pharm (Weinheim); 2023 Jan; 356(1):e2200371. PubMed ID: 36316225
[TBL] [Abstract][Full Text] [Related]
24. Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by lactoferricin.
Ohradanova-Repic A; Skrabana R; Gebetsberger L; Tajti G; Baráth P; Ondrovičová G; Praženicová R; Jantova N; Hrasnova P; Stockinger H; Leksa V
Front Immunol; 2022; 13():958581. PubMed ID: 36081512
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2.
Karimian A; Behjati M; Karimian M
Arch Virol; 2022 Oct; 167(10):1931-1946. PubMed ID: 35939103
[TBL] [Abstract][Full Text] [Related]
26. Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections.
Rosendal E; Mihai IS; Becker M; Das D; Frängsmyr L; Persson BD; Rankin GD; Gröning R; Trygg J; Forsell M; Ankarklev J; Blomberg A; Henriksson J; Överby AK; Lenman A
mBio; 2022 Jun; 13(3):e0089222. PubMed ID: 35532162
[TBL] [Abstract][Full Text] [Related]
27. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.
Beeraka NM; Sadhu SP; Madhunapantula SV; Rao Pragada R; Svistunov AA; Nikolenko VN; Mikhaleva LM; Aliev G
Front Immunol; 2020; 11():552925. PubMed ID: 33072093
[TBL] [Abstract][Full Text] [Related]
28. Would the Development of a Multitarget Inhibitor of 3CL
Dos Santos Nascimento IJ; de Moura RO
Med Chem; 2023; 19(5):405-412. PubMed ID: 36221875
[TBL] [Abstract][Full Text] [Related]
29. Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease.
Cashman DP
Med Hypotheses; 2020 Nov; 144():110027. PubMed ID: 32758873
[TBL] [Abstract][Full Text] [Related]
30. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
31. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
32. TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection.
Iwata-Yoshikawa N; Okamura T; Shimizu Y; Hasegawa H; Takeda M; Nagata N
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626688
[TBL] [Abstract][Full Text] [Related]
33. Transmembrane serine protease TMPRSS2 implicated in SARS-CoV-2 infection is autoactivated intracellularly and requires N-glycosylation for regulation.
Zhang Y; Sun S; Du C; Hu K; Zhang C; Liu M; Wu Q; Dong N
J Biol Chem; 2022 Dec; 298(12):102643. PubMed ID: 36309092
[TBL] [Abstract][Full Text] [Related]
34. Spiking dependence of SARS-CoV-2 pathogenicity on TMPRSS2.
Abbasi AZ; Kiyani DA; Hamid SM; Saalim M; Fahim A; Jalal N
J Med Virol; 2021 Jul; 93(7):4205-4218. PubMed ID: 33638460
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
36. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
37. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
[TBL] [Abstract][Full Text] [Related]
38. Peptide and peptide-based inhibitors of SARS-CoV-2 entry.
Schütz D; Ruiz-Blanco YB; Münch J; Kirchhoff F; Sanchez-Garcia E; Müller JA
Adv Drug Deliv Rev; 2020 Dec; 167():47-65. PubMed ID: 33189768
[TBL] [Abstract][Full Text] [Related]
39. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.
Wettstein L; Weil T; Conzelmann C; Müller JA; Groß R; Hirschenberger M; Seidel A; Klute S; Zech F; Prelli Bozzo C; Preising N; Fois G; Lochbaum R; Knaff PM; Mailänder V; Ständker L; Thal DR; Schumann C; Stenger S; Kleger A; Lochnit G; Mayer B; Ruiz-Blanco YB; Hoffmann M; Sparrer KMJ; Pöhlmann S; Sanchez-Garcia E; Kirchhoff F; Frick M; Münch J
Nat Commun; 2021 Mar; 12(1):1726. PubMed ID: 33741941
[TBL] [Abstract][Full Text] [Related]
40. Targeting mechanism for SARS-CoV-2
Zhao X; Luo S; Huang K; Xiong D; Zhang JZH; Duan L
Nanoscale; 2021 Nov; 13(45):19218-19237. PubMed ID: 34787160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
